Fakhreddin Jamali, D. Pharm., Ph.D.
Area of Study / Keywords
Pharmacokinetics; Inflammation; Drug development; Drug-disease interactions; Analgesics; Antiinflammatory drugs
Dr. Jamali (Doctor of Pharmacy, University of Tehran; MSc, pharmaceutics and PhD, pharmacokinetics, University of British Columbia) is a professor at the Faculty of Pharmacy and Pharm. Sci., University of Alberta. He joined the faculty at the University of Alberta in 1981.
Dr. Jamali has served as a principal investigator with the Centre of Excellence for Gastrointestinal Inflammation and Immunity Research and also with the Canadian Arthritis Network (Networks of Centres of Excellence, served as a Theme Leader). He has served as an honorary professor at the Science University of Tokyo (2010-14).
For his academic achievements and research, he has been appointed is a Fellow of the Canadian Soc. Pharm. Sci (CSPS), the American Assoc. Pharm. Sci., and the American College of Clin. Pharmacology. He has received the Killam Professorship, McKeen Cattel Memorial Award of the American College of Clin. Pharmacol., the McCalla Professorship of the University of Alberta, the McNeil Award of Assoc Canadian Faculties of Pharm., CSPS Leadership Award.
For his service to the public he has been honored with the Alberta Centennial Medal and the Alberta Pharmacy Centennial Award of Distinction.
He has been an invited or keynote speaker at many conferences.
Dr. Jamali has served as an expert witness as well as consultant and/or a member of the board of directors of many pharmaceutical houses. He has been a member of the Health Canada’s TPP Expert Advisory Committee on Bioavailabilty and Bioequivalence, and the Expert Advisory Panel on Nonsteroidal Anti-imflammatory Drugs.
He is the founding president of the Canadian Society for Pharmaceutical Sciences and founding editor of J. Pharm. & Pharm. Sci. (www.cspsCanada.org), the first open access, fully electronic peer-reviewed journal in the field.
Dr. Jamali's research interests include effect of pathophysiological changes on the action and disposition of drugs, stereochemical aspects of drugs action and disposition, basic and clinical pharmacology of anti-rheumatic, analgesic and cardiovascular drugs, and toxicology of nonsteroidal antiinfammatory drugs. He has trained 36 PhDs and published many refereed articles.
Selected published work:
H Al-Lawati, M Vakili, A Lavasanifar, Surur A, F Jamali (2020) Reduced heart exposure of diclofenac by its polymeric micellar formulation, normalizes CYP- mediated metabolism of arachidonic acid imbalance in adjuvant arthritis rat model: Implications in reduced cardiovascular side effects of diclofenac by nano-drug delivery. Molecular Pharmaceutics, Mol Pharm. 24. doi: 10.1021/acs.molpharmaceut.0c00069.
Z Alqahtani, F Jamali (2018) Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti-Inflammatory Drugs: A Systematic Review. J Pharm Pharm Sci 21: 48s-73s. doi: 10.18433/jpps29854.
A Aghazadeh-Habashi, W Asghar, , F Jamali (2017) Drug-Disease Interaction: Effect of inflammation and Nonsteroidal Anti-Inflammatory Drugs on Cytochrome P450 Metabolites of Arachidonic Acid. J Pharm Sci. DOI: 10.1016/j.xphs.2017.09.020
W Asghar, A Aghazadeh-Habashi, F Jamali (2017) Cardiovascular Effect of Inflammation and Nonsteroidal Anti-Inflammatory Drugs on Renin-Angiotensin System in Experimental Arthritis. Inflammopharmacology. doi: 10.1007/s10787-017-0344-1.
W Asghar, F Jamali (2015) The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology.23(1):1-16. doi: 10.1007/s10787-014-0225-9.
W Asghar, E Pittman, F Jamali (2015) Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.Daru J Pharrm Sci. .23:50, 1-7. doi: 10.1186/s40199-015-0133-6.
A Aghazadeh-Habashi, MH Gilzad-Kohan , W Asghar, F Jamali (2014) Glucosamine Dose/Concentration-Effect Correlation in the Rat with Adjuvant Arthritis. J Pharm Sci. 103:760-767.
S Harirforoosh, W Asghar, F Jamali (2013) Adverse Effects of Nonsteroidal Anti-inflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 16: 821-847.
A Aghazadeh-Habashi, F Jamali (2011) The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci, 14: 264 - 273, 2011.
F Sanaee, JD Clements, AWG Waugh, RN Fedorak, R Lewanczuk, F Jamali (2011) Crohn’s Disease elevates plasma concentrations of S-verapamil but reduces response to the drug proportional to disease activity. Brit J Clin Pharmacol, 72:787-97.
F Jamali (2007) Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs. Arch Intern Med 167: 2371-2.
S Hanafy, N Dagenais, WF Dryden, F Jamali (2007) The effects of Angiotensin II receptor type I blockade on Inflammation-Induced Alterations of Pharmacokinetics and Pharmacodynamics of calcium channel blockers. Brit J Pharmacol 153: 90-99.
KM Kulmatycki, F Jamali. (2006) Drug disease interactions: Role of inflammatory mediators in depression and variability in drug response. J Pharm Pharm Sci, 9:292-306.
N Dagenais, F Jamali (2005) Protective Effects of Angiotensin II Interruption: Evidence for Anti-inflammatory Actions. Pharmacotherapy, 25:1213-29.
PR Mayo, K Skeith, AS Russell, F Jamali (2000) Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 50:605-13.
LA Eliot, F Jamali (1999) Pharmacokinetics and Pharmacodynamics of Nifedipine in Atorvastatin Treated Hyperlipidemia in the Rat. J Pharmacol Exp Ther, 291:188-193.
F Jamali CM Kunz (1999) Pain-Mediated altered Absorption and Metabolism: An Explanation for Delayed Onset of Analgesia. Br J Clin Pharmacol, 47:391-396.
F Jamali; R Mehvar; FM Pasutto (1989) Stereospecific Aspects of Drug Action and Disposition: Therapeutic Pitfalls. J Pharm Sci, 78: 695 715.
Pharmacokinetics and clinical pharmacology
Dr. Jamali no longer accept trainees.